Candel Therapeutics Inc (CADL)vsEli Lilly and Company (LLY)
CADL
Candel Therapeutics Inc
$8.51
-8.20%
HEALTHCARE · Cap: $627.19M
LLY
Eli Lilly and Company
$1,117.26
+0.92%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 233061190% more annual revenue ($72.25B vs $31,000). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
CADL
Avoid24
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CADL
The strongest argument for CADL centers on Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : CADL
The primary concerns for CADL are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
CADL profiles as a value stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.52 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 24/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Candel Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Candel Therapeutics Inc. is an innovative biotechnology firm dedicated to advancing cancer treatment through its proprietary oncolytic virus technology, which selectively targets malignant cells while sparing healthy tissue. The company boasts a robust pipeline that encompasses multiple hard-to-treat cancers, enhancing anti-tumor immunity and aiming to provide significant therapeutic breakthroughs. With a strong intellectual property portfolio and collaborations with premier research institutions, Candel is strategically positioned to lead transformative developments in oncology, ultimately aiming to improve patient outcomes and redefine standard care in cancer therapy.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?